We Care About Better Therapeutics

Solving complex problems to meet patients’ needs is our mission—caring deeply about client programs is our nature

Expertise in both microbial fermentation and chemical synthesis allows us to tackle today’s development pipeline’s increasingly complex molecules. In fact, we thrive on the vexing challenges few CDMOs would have either the expertise or desire to address. Bold vision, along with the passion and commitment to make that vision reality, is at the heart of our organization.

We are a forward-thinking, North American CDMO Pharmaceutical company  specializing in clinical-to-commercial scale production capabilities for:

  • Synthetic small molecules 
  • Fermented small molecules
  • Highly potent APIs
  • Biologics 
  • Bioreagents

Flexibility, creativity, and dedication to process optimization are at the heart of our method and process development as well as quality and compliance efforts. We assure the programs advance on time and with the highest quality outcomes under our project managers’ leadership. 

Our Team Cares About Your Success

Our team comprises a healthy mix of industry veterans with long tenure in the company, a wealth of experience and proven skillsets, as well as newer talent who bring fresh thinking and new perspectives. Together, our team builds on established processes to optimize, adapt, and perfect innovative technologies and drug substance development approaches

“Flexibility is built into our DNA. The ability and dedication to solving our clients’ complex problems, no matter what it takes, is the key to our long-term relationships. ”
— Andrew Mitchell, Senior Director Business Development

BIOVECTRA in numbers

50 plus

Years of experience

1000 plus

Active clients across five geographic markets

18 out of 20

Top pharma and biotech companies supported

ten plus

Partnered capacity expansion projects since 2003

top 100

Employers in Atlantic Canada for four consecutive years

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors